Exploratory Study of Total and Free Prednisolone Plasma Exposure and Cushingoid Appearance, Quality of Life and Biochemical Toxicity in Adult Male Kidney Transplant Recipients

被引:10
作者
Bergmann, Troels K. [1 ,2 ]
Isbel, Nicole M. [3 ]
Ostini, Remo [4 ]
Barraclough, Katherine A. [5 ]
Campbell, Scott B. [3 ]
McWhinney, Brett C. [6 ]
Inder, Warrick J. [7 ,8 ]
Russell, Anthony [7 ,8 ]
Staatz, Christine E. [1 ]
机构
[1] Univ Queensland, Sch Pharm, Brisbane, Qld, Australia
[2] Odense Univ Hosp, Dept Clin Chem & Pharmacol, DK-5000 Odense C, Denmark
[3] Univ Queensland, Princess Alexandra Hosp, Dept Nephrol, Brisbane, Qld, Australia
[4] Univ Queensland, Rural Clin Sch Res Ctr, Toowoomba, Qld, Australia
[5] Royal Melbourne Hosp, Dept Nephrol, Melbourne, Vic 3050, Australia
[6] Royal Brisbane & Womens Hosp, Pathol Queensland, Dept Chem Pathol, Brisbane, Qld, Australia
[7] Princess Alexandra Hosp, Dept Endocrinol & Diabet, Brisbane, Qld 4102, Australia
[8] Univ Queensland, Sch Med, Brisbane, Qld, Australia
关键词
RENAL-TRANSPLANTATION; PHARMACOKINETICS; GLUCOCORTICOIDS; HEALTH; CYCLOSPORINE; PHARMACODYNAMICS; SENSITIVITY; TACROLIMUS; REGULATOR; STEROIDS;
D O I
10.1007/s40261-015-0334-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Objective Long-term adverse effects of oral glucocorticoids are frequent and serious. Large between-patient variability in the pharmacokinetics of prednisolone might explain why drug dose is a poor predictor of drug-related toxicity. The aim of the study was to investigate relationships between prednisolone exposure and adverse effects. Methods Male kidney transplant recipients were recruited for serial blood sampling and assessment of glucocorticoid-related adverse effects including dyslipidaemia, abnormal body fat distribution, Cushingoid appearance and impaired quality of life. Total and free prednisolone plasma concentrations were determined using ultra-high-performance liquid chromatography with tandem mass spectrometric detection. Prednisolone exposure was estimated using a limited sampling strategy. Results Fifty-six patients were recruited. Patients had a mean age of 54 years and median time post-transplantation of 75 months. Median prednisolone dose was 5 mg. Mean area under the plasma concentration-time curve was 2390 nmol h/L (+/- 580) (SD) and 175 nmol h/L (+/- 78) for total and free prednisolone, respectively. Waist to upper arm circumference ratio was positively associated with free prednisolone plasma exposure with a Spearman correlation coefficient of 0.30 (p value 0.02). The correlation coefficient was 0.24 (p value 0.08) for neck to upper arm circumference ratio and free prednisolone plasma exposure. The clinical Cushingoid phenotype as determined by the Visual Assessment of Cushing's Severity (VACS) score was associated with a reduced score relating to physical functioning on the SF-12, but there was no significant relationship between free prednisolone plasma exposure and quality-of-life scores. Lipid levels and haemoglobin A1c (HbA1c) were not associated with total or free prednisolone exposure. Conclusions There is a positive correlation between free prednisolone plasma exposure and waist to upper arm circumference ratio in adult male kidney transplant recipients on low maintenance prednisolone doses. There is no significant association between total or free prednisolone plasma exposure and plasma glucose and lipid levels in the low prednisolone dose range.
引用
收藏
页码:743 / 750
页数:8
相关论文
共 28 条
[1]   Kidney transplant outcomes are related to tacrolimus, mycophenolic acid and prednisolone exposure in the first week [J].
Barraclough, Katherine A. ;
Staatz, Christine E. ;
Johnson, David W. ;
Lee, Katie J. ;
McWhinney, Brett C. ;
Ungerer, Jacobus P. J. ;
Hawley, Carmel M. ;
Campbell, Scott B. ;
Leary, Diana R. ;
Isbel, Nicole M. .
TRANSPLANT INTERNATIONAL, 2012, 25 (11) :1182-1193
[2]   Evaluation of limited sampling strategies for total and free prednisolone in adult kidney transplant recipients [J].
Barraclough, Katherine A. ;
Isbel, Nicole M. ;
McWhinney, Brett C. ;
Ungerer, Jacobus P. J. ;
Medley, Gregory ;
Johnson, David W. ;
Hawley, Carmel M. ;
Leary, Diana R. ;
Campbell, Scott B. ;
Staatz, Christine E. .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 67 (12) :1243-1252
[3]   ENDOGENOUS AND EXOGENOUS GLUCOCORTICOIDS IN CUSHINGOID PATIENTS [J].
BENET, LZ ;
FREY, FJ ;
AMEND, WJC ;
LOZADA, F ;
FREY, BM .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1982, 16 (11) :863-868
[4]   Comparison of the Influence of Cyclosporine and Tacrolimus on the Pharmacokinetics of Prednisolone in Adult Male Kidney Transplant Recipients [J].
Bergmann, Troels K. ;
Isbel, Nicole M. ;
Barraclough, Katherine A. ;
Campbell, Scott B. ;
McWhinney, Brett C. ;
Staatz, Christine E. .
CLINICAL DRUG INVESTIGATION, 2014, 34 (03) :183-188
[5]   Clinical Pharmacokinetics and Pharmacodynamics of Prednisolone and Prednisone in Solid Organ Transplantation [J].
Bergmann, Troels K. ;
Barraclough, Katherine A. ;
Lee, Katie J. ;
Staatz, Christine E. .
CLINICAL PHARMACOKINETICS, 2012, 51 (11) :711-741
[6]   PREDNISOLONE PHARMACOKINETICS IN CUSHINGOID AND NON-CUSHINGOID KIDNEY-TRANSPLANT PATIENTS [J].
BERGREM, H ;
JERVELL, J ;
FLATMARK, A .
KIDNEY INTERNATIONAL, 1985, 27 (02) :459-464
[7]   Role of prednisolone pharmacokinetics in postchallenge glycemia after renal transplantation [J].
Bergrem, Henrik Andreas ;
Bergrem, Harald ;
Hartmann, Anders ;
Hjelmesaeth, Joeran ;
Jenssen, Trond .
THERAPEUTIC DRUG MONITORING, 2008, 30 (05) :583-590
[8]   Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids [J].
Czock, D ;
Keller, F ;
Rasche, FM ;
Häussler, U .
CLINICAL PHARMACOKINETICS, 2005, 44 (01) :61-98
[9]   Risk of cardiovascular events in people prescribed glucocorticoids with iatrogenic Cushing's syndrome: cohort study [J].
Fardet, Laurence ;
Petersen, Irene ;
Nazareth, Irwin .
BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
[10]   PHARMACOKINETICS OF PREDNISOLONE AND ENDOGENOUS HYDROCORTISONE LEVELS IN CUSHINGOID AND NON-CUSHINGOID PATIENTS [J].
FREY, FJ ;
AMEND, WJC ;
LOZADA, F ;
FREY, BM ;
HOLFORD, NHG ;
BENET, LZ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1981, 21 (03) :235-242